Gene-gene interactions protects against Familial Hypercholesterolemia: effect of lost of function PCSK9 variants

This study demonstrates that loss-of-function variants in the PCSK9 gene can mitigate the deleterious effects of an LDLR mutation, thereby protecting against Familial Hypercholesterolemia and highlighting the critical role of gene-gene interactions in the disease's phenotypic variability.

The Gist

The Big Picture: A Family with a "Broken" Cholesterol System

Imagine your body has a massive recycling plant dedicated to cleaning up "bad" cholesterol (LDL) from your blood. The main workers in this plant are called LDL Receptors. Their job is to grab the bad cholesterol and pull it out of the bloodstream to be destroyed.

Usually, if you have Familial Hypercholesterolemia (FH), it's like one of these workers is born with a broken arm. They can't grab the cholesterol effectively, so bad cholesterol builds up in your blood, leading to heart attacks at a young age.

This paper tells the story of a specific family where things got complicated. They found a "broken worker," but in one family member, the cholesterol levels were perfectly normal. Why? Because they had a secret weapon: a genetic "shield" that fixed the problem.

---

The Cast of Characters

1. The Broken Worker (LDLR Gene):
   Most people with FH have a mutation in the LDLR gene. In this family, they found a specific mutation called c.2479G>A.

   • The Analogy: Imagine the worker is trying to grab a ball (cholesterol) but their hand is slightly stiff. They can still grab it, but not as fast or efficiently as a normal person. This usually leads to high cholesterol.

2. The Boss Who Fires Workers (PCSK9 Gene):
   There is another protein in the body called PCSK9. Think of PCSK9 as a strict boss who tags the LDL receptors and sends them to the trash can before they can do their job.

   • Normal PCSK9: The boss is active and throws away good workers, making cholesterol levels go up.
   • Mutated PCSK9 (The Good Kind): Sometimes, people have mutations that break the boss. If the boss is broken, the workers stay on the job, and cholesterol levels drop. This is a "protective" mutation.

---

The Mystery of the Family

The researchers studied a large family tree. Here is what they found:

• The "Sick" Members: Many family members had the "stiff hand" mutation (LDLR). They had high cholesterol and suffered from heart disease, just as expected.
• The "Healthy" Mystery: There was one young man (let's call him Patient IV.4) who had the exact same "stiff hand" mutation as his sick relatives. By all rights, he should have had high cholesterol. But he didn't. His levels were perfect.

The Question: How did Patient IV.4 stay healthy when everyone else with the same broken gene got sick?

The Solution: The "Double Shield"

The researchers looked deeper into Patient IV.4's DNA and found the answer. He didn't just have the broken worker; he also had two mutations in the "Boss" gene (PCSK9).

1. Mutation A (c.137G>T): He had two copies of a mutation that makes the "Boss" (PCSK9) weak.
2. Mutation B (c.2023del): He had a rare, extra mutation that completely messed up the structure of the Boss, making it useless.

The Analogy:
Imagine the "stiff hand" worker (LDLR) is trying to catch balls, but they are slow.

• In the sick relatives, the "Boss" (PCSK9) is working overtime, throwing the workers into the trash. The few workers that remain are too slow to catch all the balls. Result: High Cholesterol.
• In Patient IV.4, the "Boss" is completely fired (broken by the two mutations). Even though the worker has a "stiff hand," there is no one throwing them away! Because the Boss is gone, the body keeps every single worker on the job. The sheer number of workers compensates for the fact that they are a bit slow. Result: Normal Cholesterol.

What Did the Lab Tests Show?

The scientists didn't just guess; they tested it in a lab:

• The Cell Test: They put the "stiff hand" gene into cells. The cells showed that the worker was indeed about 25% less efficient than normal.
• The Protein Test: They measured the "Boss" protein in Patient IV.4's blood. It was incredibly low. This confirmed that his body was producing almost no "Boss" to destroy the workers.

Why Does This Matter?

This study teaches us three important lessons:

1. Genes Talk to Each Other: Diseases aren't always just about one broken gene. Sometimes, a second gene can step in and fix the problem. It's like having a backup generator that kicks in when the main power fails.
2. Why Some People Are "Resilient": This explains why some people carry a "disease" gene but never get sick. They might have a hidden protective gene that we haven't looked for yet.
3. Better Medicine: If we can understand how these "protective shields" work, we might be able to design new drugs that mimic them. Instead of just trying to fix the broken worker, we could try to fire the "Boss" (which is exactly how new cholesterol drugs like PCSK9 inhibitors work today).

The Takeaway

This paper is a detective story about a family with high cholesterol. They found that one family member was healthy not because he didn't have the bad gene, but because he had a super-powerful good gene that canceled out the bad one. It proves that our DNA is a complex web of interactions, and sometimes, a little genetic luck can save the day.

Technical Summary

1. Problem Statement

Familial Hypercholesterolemia (FH) is a monogenic disorder primarily caused by loss-of-function (LOF) variants in the LDLR gene, leading to elevated LDL-cholesterol (LDL-C) and premature cardiovascular disease. However, the clinical phenotype of FH is highly heterogeneous; individuals carrying the same pathogenic variant often exhibit significant differences in lipid levels and disease severity. This variability suggests the influence of genetic modifiers.

The specific challenges addressed in this study include:

• Variant Reclassification: The LDLR c.2479G>A (p.Val827Ile) variant has a controversial history, oscillating between "Likely Pathogenic" and "Variant of Uncertain Significance" (VUS) due to conflicting functional data and its relatively high frequency in specific populations (e.g., Ashkenazi Jews).
• Phenotypic Discordance: In a specific multigenerational family, some carriers of the suspected pathogenic LDLR variant exhibited normal lipid profiles, contradicting the expected autosomal dominant inheritance pattern.
• Mechanism of Protection: The study aims to identify the genetic and functional mechanisms explaining why certain carriers remain normolipidemic despite harboring a disease-causing mutation.

2. Methodology

The researchers employed a multi-disciplinary approach combining clinical genetics, bioinformatics, functional cell assays, and protein structural modeling.

• Cohort & Clinical Data: A large multigenerational family with a clinical diagnosis of FH was recruited. Cascade genetic screening was performed on available relatives. Clinical data included lipid profiles, cardiovascular history, and physical exams.
• Genetic Analysis:
  • Targeted Next-Generation Sequencing (NGS) of a 198-gene lipid metabolism panel.
  • Focus on four major FH genes: LDLR, APOB, PCSK9, and LDLRAP1.
  • Variant classification followed ACMG/AMP and ClinGen guidelines.
  • Sanger sequencing confirmed variants and segregation.
• Functional Assays (LDLR):
  • Cell Model: CHO-ldlA7 cells (LDLR-deficient) were transfected with wild-type (WT) or mutant (LDLR c.2479G>A) cDNA.
  • Flow Cytometry: Used DiI-labeled LDL to measure LDL binding, uptake/internalization, and receptor expression.
• PCSK9 Analysis:
  • Structural Modeling: 3D modeling of the PCSK9 protein (PDB ID: 2PMW) using SWISS-MODEL and AlphaFold to assess the impact of a novel frameshift variant (PCSK9 c.2023del).
  • Quantification: Serum PCSK9 levels were measured in family members and controls using ELISA.
• Bioinformatics: In silico pathogenicity prediction (CADD, PolyPhen-2, etc.) and conservation analysis.

3. Key Contributions

• Resolution of a Controversial Variant: The study provides functional and segregation evidence supporting the pathogenicity of the LDLR c.2479G>A (p.Val827Ile) variant, despite its high population frequency in specific groups and previous reclassifications as a VUS.
• Discovery of a Novel Protective Mechanism: The paper identifies a rare, compound heterozygous PCSK9 genotype (c.137G>T homozygous + c.2023delG heterozygous) that acts as a powerful genetic modifier, completely rescuing the hypercholesterolemic phenotype in an LDLR carrier.
• Functional Characterization of a Frameshift Variant: The study characterizes the PCSK9 c.2023delG (p.Val675Leufs*130) variant, demonstrating via structural modeling that it disrupts the C-terminal cysteine-rich domain (CHRD), leading to protein misfolding and loss of function.
• Contextualizing Functional Assays: The authors discuss the limitations of CHO-cell models for LDLR variants affecting the internalization motif (FxNPxY), noting that tissue-specific adaptor redundancy (ARH vs. Dab2) may explain discrepancies between in vitro results and clinical severity.

4. Key Results

• Genetic Findings:
  • The index case and most affected family members carried the LDLR c.2479G>A variant.
  • The Exception (Individual IV.4): This individual inherited the LDLR c.2479G>A variant but had normal LDL-C levels. Genotyping revealed he was homozygous for the known LOF PCSK9 c.137G>T (p.Arg46Leu) and heterozygous for the novel PCSK9 c.2023delG (p.Val675Leufs*130).
  • Other family members carrying only the LDLR variant (without the protective PCSK9 genotype) exhibited hypercholesterolemia.
• Functional Results:
  • LDLR Activity: Flow cytometry showed the LDLR p.Val827Ile mutant retained ~74% of wild-type LDL uptake, indicating a moderate internalization defect rather than a complete loss of function.
  • PCSK9 Structure: The c.2023delG variant causes a frameshift extending the protein by 130 amino acids, disrupting the C-terminal domain's disulfide bonds (Cys678/Cys679) and predicted to cause misfolding and retention in the endoplasmic reticulum.
  • PCSK9 Levels: ELISA confirmed that Individual IV.4 had markedly reduced circulating PCSK9 protein levels compared to controls and other family members, consistent with a severe loss-of-function effect.
• Segregation Analysis: The LDLR variant cosegregated with the FH phenotype across the pedigree, except for the individual with the protective PCSK9 genotype.

5. Significance and Implications

• Gene-Gene Interactions: This study provides robust evidence that LOF variants in PCSK9 can act as potent protective modifiers, effectively counteracting the deleterious effects of pathogenic LDLR variants. This explains "resilience" in FH carriers.
• Precision Medicine: The findings underscore the necessity of broad genetic screening (beyond just the primary FH gene) when a patient's lipid phenotype does not match their genotype. Identifying protective modifiers is crucial for accurate risk stratification.
• Variant Interpretation: The study highlights the complexity of variant classification. High allele frequency in specific populations (founder effects) and context-dependent functional assays must be weighed carefully against segregation data and clinical presentation.
• Therapeutic Insight: The natural "rescue" observed in Individual IV.4 mirrors the therapeutic goal of PCSK9 inhibitors (monoclonal antibodies or siRNA), validating the mechanism of action for these drugs in a genetic context.

In conclusion, the paper demonstrates that the clinical expression of Familial Hypercholesterolemia is not solely determined by the primary pathogenic variant but is significantly modulated by the background genetic landscape, specifically the presence of protective PCSK9 variants.